FrancophonIA/ELRC3.0 huggingface dataset:
English: If you have an unrecognised DPD deficiency and take capecitabine, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects.
Danish: Hvis du har DPD-mangel uden at vide det og tager Capecitabine Teva, har du en øget risiko for akut tidlig indtræden af bivirkningerne, anført i punkt 4 ”Bivirkninger”, i svær form.
English: For combination with irinotecan, the recommended starting dose is 800 mg/m2 when administered twice daily for 14 days followed by a 7-day rest period combined with irinotecan 200 mg/m2 on day 1.
Danish: Ved kombination med irinotecan er den anbefalede initialdosis 800 mg/m2, når det administreres to gange dagligt i 14 dage efterfulgt af en pause på 7 dage kombineret med irinotecan 200 mg/m2 på dag 1.
English: • Diarrhoea: if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhoea at night.
Danish: • Diarré: hvis du har en øgning på 4 eller flere afføringer om dagen sammenlignet med det
English: For each term, the frequency count was based on ADRs of all grades.
Danish: + For hver term er hyppigheden baseret på bivirkninger af alle grader.
English: Capecitabine is not indicated in children and adolescents.
Danish: Capecitabine Teva er ikke beregnet til børn eller unge.
English: In patients with moderate renal impairment at baseline, a dose reduction to 75% for a starting dose of 1250 mg/m2 is recommended.
Danish: Til patienter med moderat nyreinsufficiens ved 5 baseline anbefales det at reducere dosis til 75 % af en initialdosis på 1.250 mg/m2.
English: Dose limiting toxicities include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia).
Danish: Dosisbegrænsende toksicitet omfatter diarré, mavesmerter, kvalme, stomatitis og hånd- og fodsyndrom (hånd- og fodhudreaktioner, palmo-plantar erythrodysæstesi).
English: In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.
Danish: Hvis du bruger blodfortyndende medicin af coumarintypen (indeholdende f.eks. phenprocoumon), kan det blive nødvendigt, at din læge ændrer dosis af denne medicin, hvis behandlingen med Capecitabine Teva stopper.
English: The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min at baseline) is increased compared to the overall population.
Danish: Incidensen af bivirkninger af sværhedsgrad 3 eller 4 er højere hos patienter med moderat nyreinsufficiens (creatininclearance 30-50 ml/min ved baseline), sammenlignet med den samlede population.
English: If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 109/L or that the platelet count drops below 75 x 10
Danish: Hvis uplanlagte laboratorieresultater under en behandlingsserie viser, at neutrofiltallet falder til under 1,0 x 109/l, eller antallet af blodplader falder til under 75 x 109/l, bør behandling med capecitabin seponeres.
English: Blister, Skin ulcer, Rash, Urticaria, Photosensitivity reaction, Palmar erythema, Swelling face, Purpura, Radiation recall syndrome
Danish: Blister, Sår i huden, Udslæt, Urticaria, Fotosensitivitets -reaktioner, Palmart erythem, Hævelse i ansigtet, Purpura, Radiation recall syndrom
English: Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection, Rhinitis, Influenza, +Infection, Oral herpes
Danish: Herpes zoster, urinvejsinfektion, oral candidiasis, øvre luftvejsinfektion, rhinitis, influenza, infektion, oral herpes
English: The AUC of 5-FU was 30%-35% higher on day 14.Capecitabine dose reduction decreases systemic exposure to 5-FU more than dose-proportionally, due to non-linear pharmacokinetics for the active metabolite.
Danish: Dosisreduktion af capecitabin nedsætter den systemiske eksponering for 5-FU mere end svarende til dosisproportionaliteten på grund af den aktive metabolits non-lineære farmakokinetik.
English: Capecitabine in combination with cisplatin was non-inferior to 5-FU in combination with cisplatin in terms of progression-free survival in the per protocol analysis (hazard ratio 0.81; 95% CI 0.63-1.04).
Danish: Capecitabin var i kombination med cisplatin non-inferiørt i forhold til 5-FU i kombination med cisplatin med hensyn til progressionsfri overlevelse i per protokolanalysen (hazard ratio 0,81; 95 % konfidensinterval 0,63-1,04).
English: Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
Danish: Mukosal inflammation, smerter i ekstremiteterne, smerter, kuldegysninger, brystsmerter, influenzalignende symptomer, +feber, infusionsrelateret reaktion, reaktion på injektionsstedet, smerter på infusionsstedet, smerter på injektionsstedet
English: • dehydration, weight loss
Danish: • dehydrering, vægttab
English: +Neutropenia, +Leucopenia, +Anaemia, +Neutropenic fever, Thrombocytopenia
Danish: Blod og lymfesystem +Neutropeni, +leukopeni, +anæmi, +neutropenisk feber, trombocytopeni
English: The hazard ratio for duration of survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio 0.85; 95% CI 0.64-1.13).
Danish: Resultatet for hazard ratio for varighed af overlevelse (samlet overlevelse) svarede til resultatet for hazard ratio for progressionsfri overlevelse (hazard ratio 0,85, 95 % konfidensinterval 0,64-1,13).
English: Dose modifications for toxicity when capecitabine is used as a 3 weekly cycle in combination with other medicinal products
Danish: Dosisændringer på grund af toksicitet, når capecitabin anvendes i tre ugers serie i kombination med andre lægemidler
English: • Stevens-Johnson syndrome: if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.
Danish: • Stevens-Johnsons syndrom: hvis du oplever smertefuldt rødt eller lilla udslæt, der spreder sig og danner blistre og/eller andre læsioner, der opstår i slimhinderne (f.eks. mund eller læber),
English: Grade 3 hand-foot syndrome is moist desquamation, ulceration, blistering and severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living.
Danish: Grad 3 hånd- og fodsyndrom defineres som fugtig afskalning, ulceration, blisterdannelse og svær smerte af hænderne og/eller fødderne og/eller svært ubehag, der forårsager at patienten ikke kan passe sit arbejde og er ude af stand til at udføre daglige aktiviteter.
English: Grade 2 hand-foot syndrome is painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient's activities of daily living.
Danish: Grad 2 hånd- og fodsyndrom defineres som smertefuld erytem og hævelse af hænderne og/eller fødderne og/eller ubehag, der påvirker patienternes daglige aktiviteter.
English: If you forget to take Capecitabine Teva
Danish: Hvis du har glemt at tage Capecitabine Teva
English: • headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling sensation),
Danish: • svimmelhed, unormal følelse i huden (følelsesløshed eller prikkende fornemmelse)
English: However, the on-treatment PFS analysis did not confirm the results of the general PFS and OS analysis: the hazard ratio of XELOX versus FOLFOX-4 was 1.24 with 97.5% CI 1.07-1.44.
Danish: Analysen af progressionsfri overlevelse on-treatment bekræftede dog ikke resultaterne fra den generelle progressionsfri overlevelse og samlede overlevelse: Hazard ratioen for XELOX versus FOLFOX-4 var 1,24 med 97,5 % konfidensinterval 1,07 - 1,44.
English: The primary efficacy analyses in the per protocol population demonstrated non-inferiority in overall survival for capecitabine- vs 5-FU-based regimens (hazard ratio 0.86; 95% CI 0.8-0.99) and for oxaliplatin- vs cisplatin-based regimens (hazard ratio 0.92; 95% CI 0.80-1.1).
Danish: Den primære virkningsanalyse i per protokolpopulationen demonstrerede non-inferioritet i samlet overlevelse for capecitabin versus 5-FU regimerne (hazard ratio 0,86; 95 % konfidensinterval 0,8-0,99) og for oxaliplatin mod cisplatinbaserede regimer (hazard ratio 0,92; 95 % konfidensinterval 0,80-1,1).
English: Do not take Capecitabine Teva - if you are allergic to capecitabine or any of the other ingredients of this medicine (listed in section 6).
Danish: - hvis du er allergisk over for capecitabin eller et af de øvrige indholdsstoffer i Capecitabine Teva lægemidlet (angivet i punkt 6).
English: Parameter: Progression-free Survival PPP ITT Parameter: Overall Survival PPP ITT *PPP=per-protocol population; **ITT=intent-to-treat population
Danish: *PPP=per-protokol population; **ITT=intent-to-treat population
English: Combination therapy with capecitabine and docetaxel in locally advanced or metastatic breast cancer Data from one multicentre, randomised, controlled phase III clinical trial support the use of capecitabine in combination with docetaxel for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline.
Danish: Kombinationsbehandling med capecitabin og docetaxel i lokal avanceret eller metastatisk brystkræft Data fra et randomiseret, kontrolleret, klinisk fase III-multicenterstudie støtter anvendelsen af capecitabin i kombination med docetaxel til behandling af patienter med lokal fremskreden eller metastatisk brystkræft hos hvem cytotoksisk kemoterapi, inklusive et antracyklin, har svigtet.
English: Capecitabine Monotherapy
Danish: Capecitabin-monoterapi
English: • joint swelling or stiffness, bone pain, muscle weakness or stiffness
Danish: • hævelse af led eller stivhed, knoglesmerter, muskelsvækkelse eller stivhed
English: In first-line treatment the median progression-free survival in the intent-to-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for capecitabine monotherapy and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI.
Danish: I 1. linjebehandlingen var den mediane progressionsfri overlevelse i intent-to-treat-populationen 5,8 måneder (95 % konfidensinterval 5,1-6,2 måneder) for capecitabin- monoterapi og 7,8 måneder (95 % konfidensinterval 7,0-8,3 måneder; p=0,0002) for XELIRI.
English: Capecitabine Teva 150 mg film-coated tablets PVC/PE/PVDC - Aluminium blister containing 10 film-coated tablets.
Danish: Capecitabine Teva 150 mg filmovertrukne tabletter PVC/PE/PVDC - Aluminiumblister med 10 filmovertrukne tabletter.
English: Sleep disorder, Anxiety
Danish: Søvnforstyrrelser, angst
English: Coumarin-derivative anticoagulants
Danish: Antikoagulantia af coumarintypen
English: Common side-effects (may affect up to 1 in 10 people) include:
Danish: Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer) omfatter:
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Danish: Bør ikke anvendes til patienter med hereditær fructoseintolerans, galactoseintolerans, galactosæmi eller glucose/galactosemalabsorption.
English: If you stop taking Capecitabine Teva
Danish: Hvis du holder op med at tage Capecitabine Teva
English: Median progression free survival ITT
Danish: Median progressionsfri overlevelse ITT konfidensinterval
English: fainting, nerve damage (neuropathy) and problems with sensation
Danish: nervebeskadigelse (neuropati) og føleproblemer
English: Upper gastrointestinal haemorrhage, Mouth ulceration, Gastritis, Abdominal distension, Gastroesophageal reflux disease, Oral pain, Dysphagia, Rectal haemorrhage, Abdominal pain lower, Oral dysaesthesia, Paraesthesia oral, Hypoaesthesia oral, Abdominal discomfort
Danish: Øvre gastrointestinal blødning, sår i munden, gastritis, abdominal distension, gastroøsofageal refluxsygdom, smerter i munden, dysfagi, rektal blødning, nedre abdominalsmerter, oral dysæstesi, oral paræstesi, oral hypoæstesi, abdominal ubehag.
English: UNIQUE IDENTIFIER - 2D BARCODE 2D barcode carrying the unique identifier included.
Danish: <Der er anført en 2D-stregkode, som indeholder en entydig identifikator.>
English: Petechiae,
Danish: Sepsis,
English: Parameter: Overall Survival PPP
Danish: Parameter: Samlet overlevelse
English: The elimination half-life (t1/2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively.
Danish: Eliminationshalveringstiden (t1/2, timer) for capecitabin, 5'-DFCR, 5'-DFUR, 5-FU og FBAL var 0,85, 1,11, 0,66, 0,76 og 3,23. capecitabin og dets metabolitter udskilles primært i urinen.
English: • fluid collection in the kidneys, increased frequency of urination during the night, incontinence,
Danish: • væskeophobning i nyrerne, øget vandladningshyppighed om natten, inkontinens, blod i urinen,
English: Given as monotherapy, the recommended starting dose for capecitabine in the adjuvant treatment of colon cancer, in the treatment of metastatic colorectal cancer or of locally advanced or metastatic breast cancer is 1250 mg/m administered twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days followed by a 7-day rest period.
Danish: Den anbefalede initialdosis ved capecitabin-monoterapi, til adjuverende behandling af kolonkræft, til behandling af metastatisk kolorektalkræft eller af lokalt fremskreden eller metastatisk brystkræft er 1.250 mg/m2 administreret to gange dagligt (morgen og aften, svarende til en daglig dosis på 2.500 mg/m2) i 14 dage, efterfulgt af 7 dages pause.
English: Constipation, Dyspepsia
Danish: Obstipation, dyspepsi
English: • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or fluorouracil,
Danish: • Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt.
English: Sepsis, Urinary tract infection, Cellulitis, Tonsillitis, Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Fungal infection, Infection, Tooth abscess
Danish: Urinvejsinfektio n, Cellulitis, Tonsillitis, Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Svampeinfektio n, Infektion, Tandbyld
English: Leucovorin 200 mg/m2 intravenous 2 hr
Danish: Leucovorin 200 mg/m2 intravenøs 2 timer
English: Pulmonary embolism, Pneumothorax, Haemoptysis, Asthma, Dyspnoea exertional
Danish: Pneumothorax, Hæmoptyse, Asthma, Funktionsdyspn ø
English: The XELIRI regimens included capecitabine 1000 mg/m2 twice daily on days 1 to 14 of a three-week cycle combined with irinotecan 250 mg/m2 on day1.
Danish: XELIRI-regimerne inkluderede capecitabin 1.000 mg/m2 2 gange dagligt på dag 1-14 i en serie på 3 uger kombineret med irinotecan 250 mg/m2 på dag 1.
English: Capecitabine Teva 500 mg film-coated tablets PVC/PE/PVDC - Aluminium blister containing 10 film-coated tablets.
Danish: Capecitabine Teva 500 mg filmovertrukne tabletter PVC/PE/PVDC - Aluminiumblister med 10 filmovertrukne tabletter.
English: Reproductive system and breast disorders
Danish: Det reproduktive system og mammæ
English: Insufficient safety and efficacy data are available in patients with hepatic impairment to provide a dose adjustment recommendation.
Danish: På grund af utilstrækkelige tilgængelige data for sikkerhed og virkning hos patienter med nedsat leverfunktion er der ingen anbefalet dosering.
English: MARKETING AUTHORISATION NUMBER(S) Capecitabine Teva 150 mg film-coated tablets EU/1/12/761/001
Danish: Capecitabine Teva 150 mg filmovertrukne tabletter EU/1/12/761/001
English: Other medicines and Capecitabine Teva
Danish: Brug af anden medicin sammen med Capecitabine Teva
English: Standard and reduced dose calculations according to body surface area for starting doses of capecitabine of 1250 mg/m2 and 1000 mg/m2 are provided in tables 1 and 2, respectively.
Danish: Standard og reducerede initialdosisberegninger af capecitabin på 1.250 mg/m2 og 1.000 mg/m2 ud fra legemsoverfladeareal er anført i henholdsvis tabel 1 og 2.
English: In combination treatment, the recommended starting dose of capecitabine should be reduced to 8001000 mg/m2 when administered twice daily for 14 days followed by a 7-day rest period, or to 625 mg/m2 twice daily when administered continuously (see section 5.1).
Danish: Ved kombinationsbehandling skal den anbefalede initialdosis af capecitabin reduceres til 800-1.000 mg/m2, når det administreres to gange daglig i 14 dage efterfulgt af en pause på 7 dage eller til 625 mg/m2 to gange daglig, når det gives kontinuerligt (se pkt.
English: Capecitabine Teva is used in the treatment of colon, rectal, gastric, or breast cancers.
Danish: Capecitabine Teva anvendes til behandling af kræft i tyktarm, endetarm, mave eller bryst.
English: Parameter: Progression-free Survival EPP ITT Parameter: Overall Survival EPP ITT *EPP=eligible patient population; **ITT=intent-to-treat population.
Danish: *EPP=egnet patientpopulation; **ITT=intent-to-treat population.
English: Table 3 Capecitabine dose reduction schedule (3 weekly cycle or continuous treatment) Toxicity grades* Dose changes within a treatment cycle
Danish: Tabel 3 Dosisreduktion af capecitabin (3-ugers serier eller kontinuerlig behandling)
English: (neuropathy) - if you have calcium imbalances (seen in blood tests) - if you have diabetes - if you cannot keep food or water in your body because of severe nausea and vomiting - if you have diarrhoea - if you are, or become dehydrated - if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests) - if you have a history of eye problems as you may need extra monitoring of your eyes - if you have a severe skin reaction
Danish: (DPD) - hvis du har lever- eller nyrelidelser - hvis du har eller har haft problemer med hjertet (f.eks. uregelmæssig hjerterytme eller smerter i brystet, kæben og ryggen som følge af fysisk anstrengelse og problemer med blodgennemstrømning til hjertet) - hvis du har sygdomme i hjernen (f.eks. kræft, som har bredt sig til hjernen eller beskadigede nerver) (neuropati) - hvis du har kalk-ubalance (ses i blodprøver) - hvis du har diabetes - hvis du ikke kan holde på mad eller vand pga. svær kvalme og opkastning - hvis du har diarré - hvis du er eller bliver dehydreret - hvis du har ionforstyrrelser i blodet (elektrolytubalance ses i blodprøver) - hvis du tidligere har haft problemer med øjnene, da du herved kan have brug for ekstra kontrol af dine øjne - hvis du har en alvorlig hudreaktion.
English: • blood clots in the veins in the lung (pulmonary embolism), collapsed lung, coughing up blood,
Danish: • blodpropper i venerne i lungen (lungeemboli), sammenklappet lunge, hosten af blod, astma,
English: - If you have any further questions, ask your doctor or pharmacist.
Danish: Er du i tvivl så spørg lægen eller apotekspersonalet.
English: Radiotherapy
Danish: Stråleterapi
English: cisplatin, irinotecan), - medicines used to treat folic acid deficiency.
Danish: bevacizumab, cisplatin, irinotecan), - lægemidler til behandling af folsyremangel.
English: In the primary analysis for DFS in the ITT population, XELOX was shown to be significantly superior to 5-FU/LV (HR=0.80, 95% CI=[0.69; 0.93]; p=0.0045).
Danish: I den primære analyse af sygdomsfri overlevelse hos ITT-populationen, viste XELOX sig at være signifikant superior i forhold til 5-FU/LV (hazard ratio = 0,80, 95 % konfidensinterval = [0,69; 0,93], p=0,0045).
English: Flushing, Hypotension, Hypertensive crisis, Hot flush, Phlebitis
Danish: Rødmen, hypotension, hypertensiv krise, hedetur, flebitis
English: A total of 156 patients were randomised to treatment with 5-FU (800 mg/m2 per day, continuous infusion on days 1 to 5 every 3 weeks) and cisplatin (80 mg/m2 as a 2-hour infusion on day 1, every 3 weeks).
Danish: I alt blev 156 patienter randomiseret til behandling med 5-FU (800 mg/m2 dagligt som kontinuerlig infusion på dag 1 til 5 hver 3. uge) og cisplatin (80 mg/m2 som en 2-timers infusion på dag 1 hver 3. uge).
English: Haematuria, Proteinuria, Creatinine renal clearance decreased, Dysuria
Danish: Hæmaturi, proteinuri, nedsat renal kreatininclearance, dysuri
English: The analysis for the secondary endpoint of RFS supports these results with a HR of 0.78 (95% CI=[0.67; 0.92]; p=0.0024) for XELOX vs. 5-FU/LV.
Danish: Analysen for det sekundære endepunkt, relapsfri overlevelse, støtter dissse resultater med en hazard ratio på 0,78 (95 % konfidensinterval = [0,67; 0,92], p=0,0024) for XELOX versus 5-FU/LV.
English: -2nd appearance -3rd appearance -4th appearance
Danish: Ved 2. forekomst Ved 3. forekomst Ved 4. forekomst
English: Hydronephrosis, Urinary incontinence, Haematuria, Nocturia, Blood creatinine increased
Danish: Hydronefrose, Urininkontinens , Hæmaturi, Nokturi, Forøget blodkreatinin
English: Each film-coated tablet contains 150 mg capecitabine.
Danish: Hver filmovertrukket tablet indeholder 150 mg capecitabin.
English: The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, the following covariates were statistically significantly associated with an increased risk of developing diarrhoea: increasing capecitabine starting dose (gram), increasing duration of study treatment (weeks), increasing age (by 10 year increments), and female gender.
Danish: En metaanalyse af 14 kliniske studier med data fra mere end 4.700 patienter, som er blevet behandlet med capecitabin, viste i alle studier kombineret, at følgende kovarianter var statistisk signifikant associeret med en øget risiko for udviklingen af diarré: stigende capecitabin-startdosis (gram), længere 14 behandlingsvarighed (uger), stigende alder (ved 10-års forøgelse) samt kvindeligt køn.
English: Oxaliplatin on Day 1, every 2 weeks Leucovorin on Days 1 and 2, every 2 weeks
Danish: Leucovorin på dag 1 og 2, hver 2. uge
English: International Normalised Ratio (INR) increased / Prothrombin time prolonged
Danish: Thrombocytope ni, Leukopeni, Hæmolytisk anæmi, Øget international normaliseret ratio (INR)/forlænget protrombintid
English: In this treatment subgroup comparison, XELOX plus bevacizumab was similar compared to FOLFOX-4 plus bevacizumab in terms of progression-free survival (hazard ratio 1.01; 97.5% CI 0.84-1.22).
Danish: Sammenligningen viste, at XELOX plus bevacizumab svarede til FOLFOX-4 plus bevacizumab med hensyn til progressionsfri overlevelse (hazard ratio 1,01; 97,5 % konfidensinterval 0,84 - 1,22).
English: Posology adjustments during treatment
Danish: Doseringsjusteringer under behandlingen:
English: Data from a multicentre, randomised, controlled phase III clinical trial in patients with advanced gastric cancer supports the use of capecitabine for the first-line treatment of advanced gastric cancer (ML17032).
Danish: Data fra et randomiseret, kontrolleret, klinisk fase III-multicenterstudie hos patienter med fremskreden ventrikelkræft støtter anvendelsen af capecitabin som 1. linjebehandling af fremskreden ventrikelkræft (ML17032).
English: Colon and colorectal cancer
Danish: Kolon- og kolorektalkræft:
English: Capecitabine 1000 mg/m2 oral twice daily
Danish: 1000 mg/m2 oral to gange dagligt
English: Angina unstable, Angina pectoris, Myocardial ischaemia, Atrial fibrillation, Arrhythmia, Tachycardia, Sinus tachycardia, Palpitations
Danish: Ustabil angina, Angina pectoris, Myokardiel iskæmi,
English: Capecitabine Teva with food and drink You should take Capecitabine Teva no later than 30 minutes after meals.
Danish: Du skal tage Capecitabine Teva senest 30 minutter efter et måltid.
English: A population pharmacokinetic analysis was carried out after capecitabine treatment of 505 patients with colorectal cancer dosed at 1250 mg/m2 twice daily.
Danish: Efter capecitabin-behandling af 505 patienter med kolorektalkræft, som fik 1250 mg/m2 to gange dagligt, blev der foretaget en populationsfarmakokinetisk analyse.
English: Herpes viral infection, Nasopharyngitis, Lower respiratory tract infection
Danish: Herpes viral infektion, Nasopharyngit is, Infektion i de nedre luftveje